Key result
Beta-blockers show no clear mortality benefit post-MI in patients with preserved LVEF.
Why the study?
Does beta-blocker therapy reduce all-cause mortality in post-MI patients with preserved LVEF (≥50%)?
Meta-Analysis (n=17,068)
Yes
Does beta-blocker therapy reduce all-cause mortality in post-MI patients with preserved LVEF (≥50%)?
Relative Risk: 0.79 (95% CI 0.55–1.06)
Routine long-term beta-blocker therapy may not provide a clear survival advantage for contemporary post-myocardial infarction patients who have a preserved ejection fraction.
Questions routine beta-blocker use for mortality reduction post-MI with preserved LVEF; leaves open need for dedicated RCTs.
Background: The role of β-blockers in MI with preserved LVEF (≥50%) remains unclear. This Bayesian meta-analysis assessed their effect on mortality and major cardiovascular outcomes. Methods: A systematic search was performed in PubMed, Embase, and Scopus from database inception to September 2025 for studies assessing BB use in post-MI patients with preserved LVEF. All-cause mortality was the primary outcome. A Bayesian random-effects model was applied using the bayesmeta package in RStudio, with effect sizes expressed as risk ratios (RRs) and 95% credible intervals (CrIs). Between-study heterogeneity was assessed through posterior τ estimates. Time-to-event outcomes were analyzed using reconstructed individual patient data from published Kaplan-Meier curves. Results: Six studies, including 17,068 patients, met the inclusion criteria. BB therapy was associated with a posterior risk ratio (RR 0.79; 95% CrI 0.55-1.06) suggesting a possible reduction in all-cause mortality; however, the credible interval included the null, indicating uncertainty in the magnitude or direction of effect. The posterior estimates for cardiovascular death (RR 0.84; 95% CrI 0.55-1.23), stroke (RR 0.92; 95% CrI 0.58-1.49), myocardial infarction (RR 1.04; 95% CrI 0.80-1.40), heart failure (RR 0.84; 95% CrI 0.55-1.23), MACE (RR 1.09; 95% CrI 0.76-1.51), and unplanned revascularization (RR 1.06; 95% CrI 0.75-1.48) also showed wide credible intervals overlapping 1.0, reflecting uncertainty in potential treatment effects. Heterogeneity across outcomes was generally low to moderate. In time-to-event analyses, the frequentist stratified model showed a statistically significant survival benefit with β-blockers (HR 0.87; 95% CI 0.81-0.92), whereas the Bayesian model indicated a similar trend, but the credible interval (HR 0.60; 95% CrI 0.26-1.41) included the null, suggesting no strong evidence of effect. Conclusion: β-blockers were not associated with a clear reduction in all-cause mortality or other outcomes, as credible intervals included the null. Large, randomized trials are needed to define their long-term role in this population.
No takes yet. Share an insight, caveat, or question.
Al-Shammari et al. (2025) conducted a meta-analysis in Myocardial infarction with preserved LVEF (≥50%) (n=17,068). Beta-blockers vs. No beta-blockers was evaluated on All-cause mortality (RR 0.79, 95% CI 0.55-1.06). Beta-blocker therapy did not demonstrate a clear reduction in all-cause mortality compared to no beta-blocker use in post-myocardial infarction patients with preserved LVEF (RR 0.79).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: